Evidence map›Paper›PMID 40510443›Full record

ArticleBMJ oncology2025

Osteoclast-expanded supercharged NK cells perform superior antitumour effector functions.

Meng-Wei Ko, Ao Mei, Emanuela Senjor, Milica Perišić Nanut, Lucy Wanrong Gao, Paul Wong, Po-Chun Chen, Whitaker Cohn, Julian P Whitelegge, Janko Kos and 3 more

Abstract read
In one paragraph

Article in BMJ oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Meng-Wei Ko *Division of Oral Biology and Medicine, The Jane and Jerry Weintraub Center for Reconstructive Biotechnology, University of California Los Angeles School of Dentistry, Los Angeles, California, USA.
Ao Mei *Department of Microbiology and Immunology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Emanuela SenjorDivision of Oral Biology and Medicine, The Jane and Jerry Weintraub Center for Reconstructive Biotechnology, University of California Los Angeles School of Dentistry, Los Angeles, California, USA.
Milica Perišić NanutDepartment of Biotechnology, Jožef Stefan Institute, Ljubljana, Slovenia.
Lucy Wanrong GaoSemel Institution, University of California Los Angeles, Los Angeles, California, USA.
Paul WongDivision of Oral Biology and Medicine, The Jane and Jerry Weintraub Center for Reconstructive Biotechnology, University of California Los Angeles School of Dentistry, Los Angeles, California, USA.
Po-Chun ChenDivision of Oral Biology and Medicine, The Jane and Jerry Weintraub Center for Reconstructive Biotechnology, University of California Los Angeles School of Dentistry, Los Angeles, California, USA.
Whitaker CohnSemel Institution, University of California Los Angeles, Los Angeles, California, USA.
Julian P WhiteleggeSemel Institution, University of California Los Angeles, Los Angeles, California, USA.
Janko KosDepartment of Biotechnology, Jožef Stefan Institute, Ljubljana, Slovenia.
Kawaljit KaurDivision of Oral Biology and Medicine, The Jane and Jerry Weintraub Center for Reconstructive Biotechnology, University of California Los Angeles School of Dentistry, Los Angeles, California, USA.ORCID 0000-0003-1936-5985
Subramaniam MalarkannanDepartment of Microbiology and Immunology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Anahid JewettDivision of Oral Biology and Medicine, The Jane and Jerry Weintraub Center for Reconstructive Biotechnology, University of California Los Angeles School of Dentistry, Los Angeles, California, USA.

Funding

GATA2-TGF beta-TAL1 pathway as a critical mediator of NK Cell developmentR01AI183571 · NIAID · MEDICAL COLLEGE OF WISCONSIN · PI BARBARA L. KEE, Subramaniam Malarkannan · 2025 to 2026
$1.5M
NIAID NIH HHS R01 AI183571
6 · The paper itself

Abstract

Objective: Natural killer (NK) cells are the largest innate lymphocyte subset with potent antitumour and antiviral functions. However, clinical utilisation of human NK cells is hampered due to a lack of reliable methods to augment their antitumour potential. We demonstrated technology in which human NK cells were cocultured with osteoclasts in the presence of probiotic bacteria. This approach significantly augmented the antitumour cytotoxicity and polyfunctionality of human NK cells, resulting in the generation of supercharged NK (sNK) cells. Methods and analysis: We explored the proteomic, transcriptomic and functional characterisation of sNK cells using cell imaging, flow cytometric analysis, 51-chromium release cytotoxicity assay, ELISA, ELIspot, IsoPLexis single-cell secretome analysis, proteomic analysis, RNA analysis, western blot and enzyme kinetics. Results: We found that sNK cells were less susceptible to split anergy and tumour-induced exhaustion. Proteomic analyses revealed that sNK cells significantly increased their cell motility and proliferation. Single-cell transcriptomes uncovered sNK cells undertaking a unique differentiation trajectory and turning on STAT1, JUN, BHLHE40, ELF1, MAX and MYC regulons essential for augmenting antitumour effector functions and proliferation, respectively. Both proteomic and single-cell transcriptomes revealed that an increase in Cathepsin C helped to augment the quantity and function of Granzyme B. Conclusions: These results support that this unique method produces potent NK cells for clinical utilisation and delineate the molecular mechanisms associated with this process.

Indexed as

CytokinesCytotoxicityHead and neck cancerImmunotherapy

Identifiers

PMID40510443
PMCPMC12161327

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.